Rachael OConnor
Overview
Explore the profile of Rachael OConnor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaynor K, McNamara R, OConnor R, Schmieder L, Somers E, Hennessy E
Psychiatry Res
. 2023 Aug;
327:115414.
PMID: 37604042
This paper explored cognitive responses to the COVID-19 pandemic in those selfreporting depressive symptoms during a period of realistic health, economic and social threat. Negative cognitions are a key therapy...
2.
Delz A, Gaynor K, OConnor R, Schmieder L, Somers E
Acta Psychol (Amst)
. 2023 Feb;
234:103861.
PMID: 36774772
The mental health impact of the COVID-19 pandemic has been significant, with many regions across the globe reporting significant increases in anxiety, depression, trauma, and insomnia. This study aims to...
3.
Okada T, Lee A, Qin L, Agaram N, Mimae T, Shen Y, et al.
Cancer Discov
. 2016 Sep;
6(10):1148-1165.
PMID: 27577794
Significance: Identifying the molecular pathogenesis for myxofibrosarcoma progression has proven challenging given the highly complex genomic alterations in this tumor type. We found that integrin-α10 promotes tumor cell survival through...
4.
Crago A, Chmielecki J, Rosenberg M, OConnor R, Byrne C, Wilder F, et al.
Genes Chromosomes Cancer
. 2015 Jul;
54(10):606-15.
PMID: 26171757
CTNNB1 mutations or APC abnormalities have been observed in ∼85% of desmoids examined by Sanger sequencing and are associated with Wnt/β-catenin activation. We sought to identify molecular aberrations in "wild-type"...
5.
Kovatcheva M, Liu D, Dickson M, Klein M, OConnor R, Wilder F, et al.
Oncotarget
. 2015 Mar;
6(10):8226-43.
PMID: 25803170
CDK4 inhibitors (CDK4i) earned Breakthrough Therapy Designation from the FDA last year and are entering phase III clinical trials in several cancers. However, not all tumors respond favorably to these...
6.
Harmsen S, Huang R, Wall M, Karabeber H, Samii J, Spaliviero M, et al.
Sci Transl Med
. 2015 Jan;
7(271):271ra7.
PMID: 25609167
The inability to visualize the true extent of cancers represents a significant challenge in many areas of oncology. The margins of most cancer types are not well demarcated because the...
7.
Chmielecki J, Crago A, Rosenberg M, OConnor R, Walker S, Ambrogio L, et al.
Nat Genet
. 2013 Jan;
45(2):131-2.
PMID: 23313954
Solitary fibrous tumors (SFTs) are rare mesenchymal tumors. Here, we describe the identification of a NAB2-STAT6 fusion from whole-exome sequencing of 17 SFTs. Analysis in 53 tumors confirmed the presence...
8.
Crago A, Socci N, Decarolis P, OConnor R, Taylor B, Qin L, et al.
Clin Cancer Res
. 2012 Jan;
18(5):1334-40.
PMID: 22241790
Purpose: Molecular events underlying progression of well-differentiated liposarcoma (WDLS) to dedifferentiated liposarcoma (DDLS) are poorly defined. This study sought to identify copy number alterations (CNA) associated with dedifferentiation of WDLS,...
9.
Wu Y, Okada T, Decarolis P, Socci N, OConnor R, Geha R, et al.
Genes Chromosomes Cancer
. 2011 Dec;
51(4):313-27.
PMID: 22170698
Well-differentiated liposarcoma (WDLS) and dedifferentiated liposarcoma (DDLS) represent the most common biological group of liposarcoma, and there is a pressing need to develop targeted therapies for patients with advanced disease....
10.
Ugras S, Brill E, Jacobsen A, Hafner M, Socci N, DeCarolis P, et al.
Cancer Res
. 2011 Jun;
71(17):5659-69.
PMID: 21693658
Liposarcoma remains the most common mesenchymal cancer, with a mortality rate of 60% among patients with this disease. To address the present lack of therapeutic options, we embarked upon a...